hCRLF2/hIL7R/hTSLP
Nomenclature
C57BL/6JSmo-Tslptm2(hTSLP)Crlf2tm1(hCRLF2)Il7rtm1(hIL7R)Smoc
Cat. NO.
NM-XA-241555
Strain State
Repository Live
Model Description
Validation Data
Fig.1 Detection of CRLF2 expression in adrenal gland by RT-PCR. Mouse Crlf2 mRNA (214 bp) was detectable only in WT C57BL/6 mice. Human CRLF2 mRNA (182 bp) was detectable only in HO/HO/HO hCRLF2/hIL7R/hTSLP mice but not in WT mice. Adrenal gland RNA was extracted from 9-week-old male WT C57BL/6 (WT)(n=3) and HO hCRLF2/hIL7R/hTSLP mice (HO/HO/HO) (n=3), then cDNA libraries were synthesized by reverse transcription, followed by PCR with mRNA primers.
Abbr. M, marker; HO, homozygous; WT, wild type.
Fig.2 Detection of IL7R expression in spleen by RT-PCR. Mouse Il7r mRNA (310 bp) was detectable only in WT C57BL/6 mice. Human IL7R mRNA (167 bp) was detectable only in HO/HO/HO hCRLF2/hIL7R/hTSLP mice but not in WT mice. Spleen RNA was extracted from 9-week-old male WT C57BL/6 (WT)(n=3) and HO hCRLF2/hIL7R/hTSLP mice (HO/HO/HO) (n=3), then cDNA libraries were synthesized by reverse transcription, followed by PCR with mRNA primers.
Abbr. M, marker; HO, homozygous; WT, wild type.
Fig.3 Detection of TSLP expression in bladder by RT-PCR. Mouse Tslp mRNA (160 bp) was detectable only in WT C57BL/6 mice. Human TSLP mRNA (168 bp) was detectable only in HO hCRLF2/hIL7R/hTSLP mice but not in WT mice. Bladder RNA was extracted from 9-week-old male WT C57BL/6 (WT)(n=3) and HO hCRLF2/hIL7R/hTSLP mice (HO/HO/HO) (n=3), then cDNA libraries were synthesized by reverse transcription, followed by PCR with mRNA primers.
Abbr. M, marker; HO, homozygous; WT, wild type.
Fig.4 Detection of IL7R expression on T cells in spleen of WT C57BL/6 mice and HO/HO/HO hCRLF2/hIL7R/hTSLP mice by FACS. hIL7R was exclusively detectable in hCRLF2/hIL7R/hTSLP humanized mice but not in WT mice，whereas mIL7R was exclusively detectable on T cells in WT C57BL/6 mice. Leukocytes were collected from spleen of wild-type C57BL/6 mice (male, 8 weeks old) and homozygous hCRLF2/hIL7R/hTSLP humanized mice (male, 8 weeks old) 4h post LPS stimulation（5mg/kg, i.p.) and analyzed by flow cytometry with anti-mIL7R and anti-hIL7R.
Abbr. HO/HO/HO, homozygous; WT, wild type.
Fig.5 Detection of mTSLPR expression on DC and macrophage cells in spleen of WT C57BL/6 mice and HO/HO/HO hCRLF2/hIL7R/hTSLP mice by FACS. mTSLPR was exclusively detectable on DC and macrophage cells in wild-type mice but not in hCRLF2/hIL7R/hTSLP humanized mice. Leukocytes were collected from spleen of wild-type C57BL/6 mice (male, 8 weeks old) and homozygous hCRLF2/hIL7R/hTSLP humanized mice (male, 8 weeks old) 4h post LPS stimulation (5mg/kg, i.p.) and analyzed by flow cytometry with anti-mTSLPR.
Abbr. HO/HO/HO, homozygous; WT, wild type.
Fig.6 Detection of hTSLPR expression on DC and macrophage cells in spleen of WT C57BL/6 mice and HO/HO/HO hCRLF2/hIL7R/hTSLP mice by FACS. hTSLPR was exclusively detectable on DC and macrophage cells in hCRLF2/hIL7R/hTSLP humanized mice but not in WT mice. Leukocytes were collected from spleen of wild-type C57BL/6 mice (male, 8 weeks old) and homozygous hCRLF2/hIL7R/hTSLP humanized mice (male, 8 weeks old) 4h-post LPS stimulation (5mg/kg, i.p.), and analyzed by flow cytometry with anti-mTSLPR.
Abbr. HO/HO/HO, homozygous; WT, wild type.
Fig.7 Detection of hTSLPR expression on DC and macrophage cells in spleen of WT C57BL/6 mice and HO/HO/HO hCRLF2/hIL7R/hTSLP mice by FACS. Leukocytes were collected from spleen of WT C57BL/6 mice (male, 8 weeks old) and HO hCRLF2/hIL7R/hTSLP humanized mice (male, 8 weeks old) 4h-post LPS stimulation（5mg/kg, i.p.), and analyzed by flow cytometry with anti-mTSLPR.
Abbr. HO/HO/HO, homozygous; WT, wild type.
You may also like
Shanghai Model Organisms Center Inc has licensed CRISPR-Cas9 technology from Broad Institute
On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.
Learn moreWorkshop：Progress and Advances in Preclinical immuno-Oncology Research
SMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.
Learn moreCustomizing Mouse Models: Delivering in 100 Days to Speed Up Your Research!
At GenoBioTX, we understand that the lengthy wait times for gene-modified mouse models can hinder your research progress. Traditional methods often require 6-9 months, leading to delays and increased costs. That’s why we’re thrilled to introduce our innovative service designed to streamline this process and deliver results faster.
Learn more
